Gowling WLG advised NurExone on the private placement.NurExone Biologic Inc., a biopharmaceutical company pioneering the development of non-invasive ExoTherapy for treating traumatic spinal cord injuries, announced…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
